BELITE BIO INC - AMER

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

13 май 2025 21:00:36 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in Four Upcoming Investor Conferences

12 май 2025 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results

07 май 2025 08:00:01 Источник Nasdaq GlobeNewswire

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting

29 апр 2025 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

17 мар 2025 06:00:34 Источник Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

17 мар 2025 06:00:02 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

11 мар 2025 03:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

04 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

27 фев 2025 02:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Registered Direct Offering of $15 Million

05 фев 2025 22:35:00 Источник Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

12 ноя 2024 01:00:25 Источник Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

05 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03 ноя 2024 16:00:27 Источник Nasdaq GlobeNewswire

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

08 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

10 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

03 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09 авг 2024 16:30:00 Источник Nasdaq GlobeNewswire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire